Full-Time

Senior Analytical Scientist I

Posted on 10/3/2024

Arcellx

Arcellx

51-200 employees

Develops immunotherapies for cell therapy

No salary listed

Senior, Expert

North Bethesda, MD, USA

Relocation assistance is offered for roles if required.

Relocation assistance is offered for roles if required.

Relocation assistance is offered for roles if required.

Category
Computational Biology
Biology Lab & Research
Biology & Biotech
Requirements
  • Bachelor’s degree with 10+ years of relevant work experience, or master’s degree with 8+ years’ experience, or PhD in relevant scientific discipline with 2+ years of postdoc or industry experience on protein or virus analysis.
  • Solid background knowledge and practical experience in biophysical techniques to characterize aggregates, subvisible and visible particles in proteins and/or viral vector products, such as flow imaging techniques, HIAC, NTA, SEC-MALS, FFF-MALS, DLS/SLS, etc.
  • Hands-on experience in thermodynamic analysis (DSC or DSF) to support formulation development or product characterization.
  • Prior experience in particle characterization and investigation in the late stage of CMC development is highly desired.
  • Experience in drafting and reviewing technical documents including analytical method SOPs, characterization protocols and reports.
  • Excellent collaborator with strong communication skills.
  • Proven self-starter with a high attention to scientific details and strong problem-solving skills.
Responsibilities
  • Serve as a biophysics SME (subject matter expert) in CMC activities including pre-formulation study, formulation development, in-process monitoring, product characterization, particle characterization and investigation.
  • Collaborate with a dynamic and engaging team of Arcellx scientists and CDMO partners to perform biophysical characterization and thermodynamic analysis on protein and lentivirus products.
  • Build strategies for protein or virus product quality analytical testing throughout the product lifecycle development.
  • Participate in designing long-term stability studies per regulatory guidelines and perform stability data trending analysis for drug substances, drug products and reference standards.
  • Design and coordinate accelerated and stressed stability study for manufacturability assessment, analytical method development, formulation development, CQA assessment and comparability study.
  • Author and review technical documents.
  • Perform and troubleshoot analytical assays to support CMC and some research activities.
  • Present scientific study design and findings at internal and external meetings.
Desired Qualifications
  • Experience in applying Design of Experiment (DOE) and other appropriate statistics approaches during formulation development, analytical method development and robustness study.

Arcellx develops immunotherapies aimed at improving cell therapy for serious diseases. Their products focus on harnessing the body's immune system to fight illnesses. The company works closely with healthcare providers and research institutions to create and bring these treatments to market. Unlike many competitors, Arcellx emphasizes proprietary technologies in their immunotherapy products, which allows them to target specific medical needs more effectively. The goal of Arcellx is to provide safe and effective treatment options for patients with unmet medical needs.

Company Size

51-200

Company Stage

IPO

Headquarters

Gaithersburg, Maryland

Founded

2014

Simplify Jobs

Simplify's Take

What believers are saying

  • Partnership with Kite enhances Arcellx's multiple myeloma program development.
  • Recent clinical data shows robust long-term responses for CART-ddBCMA.
  • Advancements in gene editing could improve Arcellx's CAR-T product efficacy.

What critics are saying

  • Competition from Legend Biotech and Johnson & Johnson's Carvykti is significant.
  • High costs of CAR-T therapies may limit market adoption and accessibility.
  • Dependence on partnerships like Kite could pose strategic risks.

What makes Arcellx unique

  • Arcellx's CART-ddBCMA has Fast Track and Orphan Drug designations from the FDA.
  • The ARC-SparX platform offers dosable and controllable CAR-T therapy options.
  • Anito-cel uses a novel D-Domain BCMA binder for enhanced multiple myeloma cell targeting.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Unlimited Paid Time Off

Flexible Work Hours

401(k) Company Match

Fully-Paid Parental Leave

Tuition Reimbursement

Relocation Assistance

Growth & Insights and Company News

Headcount

6 month growth

↓ -3%

1 year growth

↑ 1%

2 year growth

↓ -3%
Business Wire
May 21st, 2025
Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025

Arcellx announces its participation at TD Cowen's 6th Annual Oncology Innovation Summit and its investor event During EHA2025.

Business Wire
Mar 20th, 2025
Arcellx Appoints Andrew Galligan and Kristin Myers to Its Board of Directors

Arcellx appoints Andrew Galligan and Kristin Myers to its Board of Directors.

BioSpace
Feb 28th, 2025
Arcellx To Participate At The Td Cowen 45Th Annual Health Care Conference

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on Wednesday, March 5, at 1:10 p.m. ET.A live webcast of this discussion will be accessible from Arcellx’s website at www.arcellx.com in the Investors section. A replay of the webcast will be archived and available for 30 days following the event.About Arcellx, Inc.Arcellx, Inc. is a clinical-stage biotechnology company reimagining cell therapy by engineering innovative immunotherapies for patients with cancer and other incurable diseases. Arcellx believes that cell therapies are one of the forward pillars of medicine and Arcellx’s mission is to advance humanity by developing cell therapies that are safer, more effective, and more broadly accessible

Business Wire
May 9th, 2024
Kite And Arcellx Continue Momentum With Advances In Anito-Cel Multiple Myeloma Program

REDWOOD CITY, Calif. SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX) today announced several key operational updates on their partnered anitocabtagene autoleucel (anito-cel) multiple myeloma program. Anito-cel is the first BCMA CAR T to be investigated in multiple myeloma that utilizes Arcellx’s novel and compact D-Domain binder. The companies shared the design of a global, Phase 3 randomized controlled clinical trial, iMMagine-3, which Kite expects to start in the second half of this year. The trial will compare the efficacy and safety of anito-cel randomized against the standard of care (SOC) in patients with relapsed and/or refractory multiple myeloma (rrMM) who have received one to three prior lines of therapy, including an immunomodulatory drug (lMiD) and an anti-CD38 monoclonal antibody

Business Wire
May 9th, 2024
Arcellx And Kite Continue Momentum With Advances In Anito-Cel Multiple Myeloma Program

REDWOOD CITY, Calif. SANTA MONICA, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX) and Kite, a Gilead Company (NASDAQ: GILD), today announced several key operational updates on their partnered anitocabtagene autoleucel (anito-cel) multiple myeloma program. Anito-cel is the first BCMA CAR T to be investigated in multiple myeloma that utilizes Arcellx’s novel and compact D-Domain binder. The companies shared the design of a global, Phase 3 randomized controlled clinical trial, iMMagine-3, which Kite expects to start in the second half of this year. The trial will compare the efficacy and safety of anito-cel randomized against the standard of care (SOC) in patients with relapsed and/or refractory multiple myeloma (rrMM) who have received one to three prior lines of therapy, including an immunomodulatory drug (lMiD) and an anti-CD38 monoclonal antibody

INACTIVE